New approaches to the treatment of gastro-lntestinal cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 508-519

  Waters, Justin S ^a   Ross, Paul J ^a   Popescu, Razvan A ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Gastrointestinal cancer; Radiotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 ETHYNYLURACIL; ANGIOGENESIS INHIBITOR; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NOLATREXED; OCTREOTIDE; OXALIPLATIN; OXONIC ACID; PACLITAXEL; PEMETREXED; PYRIDINE DERIVATIVE; RALTITREXED; TAXANE DERIVATIVE; TEGAFUR; THYMIDYLATE SYNTHASE INHIBITOR; UFT; UNINDEXED DRUG; VITAMIN D;

ADVERSE DRUG REACTION; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CELLULITIS; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; ESOPHAGUS CANCER; GENE THERAPY; GRANULOCYTOPENIA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM CANCER; STOMACH CANCER; STOMATITIS;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG THERAPY; ESTROGEN REPLACEMENT THERAPY; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; RADIOTHERAPY;

EID: 0030721615     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201494     Document Type: Article

References (78)

1. Cunningham D, Zalchcrg JR, Ralh U, Olver I, Van Cutscn E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K: Tomudex ZD 1694: Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia, Eur J Cancer 1995:31A: 1945-1954.
2. Miller KD, Loehrer PJ, Picus J, Blanke C, John W, Clark J, Shulman L, Burris H, Thornton D: A phase II trial of LY231514 in patients with unresectable pancreatic cancer, Proc Am Soc Clin Oncol 1997:16:abstr 1060.
3. Loh K, Stuart K, Cohn A, White C, Hines J, Miller W, Green MR, Chew T, Johnston A, Clcndennin N: A phase II trial of Thymitaq" (AG337) in patients with adenocarcinoma of the pancreas, Proc Am Soc Clin Oncol 1997:16: abstr 938.
4. Pazdur R, Lasserc Y, Rhodes V, Ajani JA, Sug-arman SM, Patt YZ, Joncs DV, Markowitz AB, Abbruzzcse JL, Breadv B, Levin B: Phase 11 trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma, J Clin Oncol 1994:12:2296-2300.
5. Findly M, Van Cutsen E, Kocha W, Allman D, LatTranchi B, Griffin T, Ostcrwalder B, Dailey D, Pazdur R, Verweij J: A randomised phase II study of Xeloda’ (capecitabinc) in patients with advanced colorectal cancer, Proc Am Soc Clin Oncol 1997; 16:abstr 798.
6. Baker SD, Khor SP, Adjci AA, Doucette M, Spector T, Donchowcr RC, Grochow LB, Sar-lorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability and safely study of lluorouraeil in patients treated with 776C85, an inactivator of dihydropyrim-idinc dehydrogenase, J Clin Oncol 1996:14: 3085-3096.
7. Schilsky R, Bukowski R, Burris H, Crawford J, Hochster H, O’rourke M, Stcinfcldt H, Doucette M, Levin J, Hochnckcr J: A phase 11 study of a five day regimen of oral 5-fluorouracil plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol 1997; 16:abstr 961.
8. Rustum YM, Cao S, Shirasaka T, Taguchi T: A new 5-0uorouracil prodrug, S-1, orally biovail-able with high therapeutic index in model system active in phase II clinical trials, Pick Am Soc Clin Oncol 1997; 16:abstr 799.
9. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouam Y, Yehou M, Marty M, Extra JM, Bonneterrc J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Négrier S, Merrouche Y, Burki F, Mousseau M, Hcrait P, Mahjoubi M: A phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naïve patients and patients prc-treated with 5-Fll based chemotherapy, J Clin Oncol 1997;15:251-260.
10. Conti JA, Kemeny NE, Saallz LB, Huang Y, Tong WP, Chou T-C, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer, J Clin Oncol 1996:14:709-715.
11. Pitot HC, Wender D, O’connell MJ, Wicand HS, Mailliard JA: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study, Proc Am Soc Clin Oncol 1994; 13:abstr 573.
12. Rothenberg ML, Eckardt JR, Kuhn JG, Burris AA III, Nelson J, Hilsenbcck SG, Rodriguez Gl, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Ellring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer, J Clin Oncol 1996:14:1128-1135.
13. Shimada Y, Yashino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-I1, a new camptothecin derivative in metastatic colorectal cancer, J Clin Oncol 1993:11:909-913.
14. Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N: Simultaneous administration of CPT-II and lluorouraeil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer, J Natl Cancer Inst 1994:86:1096-1098.
15. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Bcrkcry R, Stcger S, Eng M, Dietz A, Locker P, Kelsen DP: A phase I clinical and pharmacokinetic study of irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced solid tumours, J Clin Oncol 1996:14:2959-2967.
16. Grossin F, Barbaull H, Benhammouda A, Rixe O, Antoine E, Auclerc G, Weil M, Nizri D, Farabos C, Mignard D, Mahjoubi M, Khayat D, Bastian G: A phase I pharmacokinetics study of concomitant CPT-11 and 5FU combination (abstract), Annu Meet AACR, Washington, April, 1996.
17. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda K, Yoshida S: Phase I-II study of irino-teean hydrochloride combined withcisplatin in patients with advanced gastric cancer, J Clin Oncol 1997;15:921-927.
18. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegcnthaler P, Puitenhuis M, Mathicu-Boue A, Verwcij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, and EORTC Early Clinical Trials Group Study, Ann Oncol 1995;6:129-132.
19. Machover D, Moreau S, de Gramonl A, Gas-tiaburu J, Brienza S, Louvet C, Varette C, Kru-lik M, Missel JL: Phase II trial of oxaliplatin: L-OHP in patients with colorectal carcinoma previously resistant to fluorouracil and folinic acid, Proc Am Soc Clin Oncol 1993; 12:abstr 645.
20. Becouam Y, Yeliou M, Ducreux M, Boral C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Rougier P, Nguvcn TD, Paillot B, Raoul JL, Fandi A: Oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients: Preliminary activity/toxicity report, Proc Am Soc Clin Oncol 1997; 16:abstr 804.
21. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer, Eur J Cancer 1997:33: 214-219.
22. Levi F, Dagliott L, Perpoint B, Zidani R, Giacchetti S, Chollct P, Le Roi A, Llory JF, Focan C, Kunstlingcr F, Adam R, Vannetzel JM, Le-toumeau Y, Jasmin C, Bismuth H, Misset JL: A multicentre phase II trial of chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer, Proc Am Soc Clin Oncol 1997; 16
23. Ajani JA, llson DH, Daugherty K, Pazdur R, Lynch PM, Kelscn DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the oesophagus, J Nall Cancer Inst 1994:86:1086-1091.
24. Ajani JA, llson DH, Bhalla K, Forastiere A, Pazdur R, Martin L, Daugherty K, Kelsen DP: Taxol, cisplatin, 5FU: A multi-institutional phase II study in patients with carcinoma of the oesophagus, Proc Am Soc Clin Oncol 1995:14: abstr 489.
25. Costa F, llson D, Forastiere A, Patel P, Heelan R, Huang Y, Bcrtness B, Arquette M, Urba S, Ochoa M, Kelsen D: Phase II study of paclitax-el and cisplatin in patients with advanced adenocarcinoma or squamous cell carcinoma of the oesophagus, Proc Am Soc Clin Oncol 1997; 16:abstr 930.
26. Einzig AI, Lipsilz S, Wiemik PH, Benson AB III: Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract, The Eastern Cooperative Oncology Group ECOGl results, invest New Drugs 1995:13:223-227.
27. Ajani JA, Fairweather J, Dumas P, Pazdur R, Mansfield PF: A phase II study of taxol in patients with advanced untreated gastric carcinoma, Proc Am Soc Clin Oncol 1997; 16:abstr 933.
28. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermerken JB, Kaye S, Wanders J, Franklin H, LeBail N, Vcrwcij J: Docetaxel in advanced gastric cancer: Results of a phase II clinical trial, Br J Cancer 1994:70:380-383.
29. Einzig AI, Neuberg D, Rcmick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB III: Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The ECOG results of Protocol E1293, Med Oncol 1996;13:87-93.
30. Taguchi T: A late phase II studs of docetaxel in patients with gastric cancer, Proc Am Soc Clin Oncol 1997; 16:abstr 934.
31. Murad AM, Tinoco LA, Guimaracs RC, Proco-pio R, Aragao BC, Ferreira-Filho AF, Schwartsmann G: Paclitaxel plus 5-fluoroura-cil: A novel and very active regimen for advanced gastric cancer, A phase II trial, Proc Am Soc Clin Oncol 1997:16:abstr 1063.
32. Kim JS, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim JS, Song CW, Ryu HS, Hyun JH, Kim YH: A phase II trial oftaxol, cisplatin and 5-fluorouracil in patients with advanced gastric carcinomas, Proc Am Soc Clin Oncol 1977:16: abstr 1043.
33. Rougicr P, Adcnis A, Ducreux M, et al: Phase II study of docetaxel in pancreatic adenocarcinoma: Final results after extra-mural review (abstract 126), 2nd Int Conf on Biology, Prevention andTreatment of Gastrointestinal Malignancies, Köln, January 1995.
34. Casper ES, Green MR, Kelsen DP, Hcclan RT, Brown TD, Flonibaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gcmcitabinc (2.2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas, Invest New Drugs 1994:12:29-34.
35. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spicssi G, Blatter J: Phase II study of gcmcitabinc in patients with advanced pancreatic cancer, Br J Cancer 1996:73:101-105.
36. Moore M, Andersen J, Burris II, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Neison R, et al: A randomized trial of gcmcitabinc (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer, Proe Am Soc Clin Oncol 1995:14:abstr 473.
37. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer, Ann Oncol 1996:7:347-353.
38. Christman K, Kelsen D, Saltz L, Tarassoff PG: Phase II trial of gemcitabine in patients with advanced gastric cancer, Cancer 1994:73:5-7.
39. Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, Ten-Bokkel-Huinink W, Vcrmorkcn J, Wanders J, Franklin H, Verwcij J: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of EORTC Early Clinical Trials Group: Ann Oncol 1994:5:471-472.
40. Fink U, Molle B, Daschner H, Ermisch S, Löffel J, Herrmann R: Phase II study of gemcitabine in metastatic colorectal cancer, Proc Am Soc Clin Oncol 1992;11:abstr 507.
41. Moore DF Jr., Pazdur R, Daugherty K, Taras-solf P, Abbruzzese JL: Phase II study of gemcitabine in advanced colorectal adenocarcinoma, Invest New Drugs 1992:10:323-325.
42. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohvanta S, Sasako M, Van de Velde CJH: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomised trials, J Clin Oncol 1993:11:1441-1447.
43. Kelsen DP: Adjuvant and neoadjuvanl therapy for gastric cancer, Semin Oncol 1996:23:379-389.
44. Herskovic A, Martz K, Al-Sarraf M, Lcichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus, N Engl J Med 1992:326:1593-1598.
45. Le Prise E, Etienne PL, Meunier B, Maddcrn G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, I.aunoisB: A randomised study of chemotherapy, radiation therapy, and surgery versus surgery for localised squamous cell carcinoma of the oesophagus, Cancer 1994:73:1779-1784.
46. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ: A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma, N Engl J Med 1996:335: 462-467.
47. Urba S, Orringer M, Turrisi A, Wlme R, lanet-toni M, Forastiere A: A randomised trial comparing surgery to prcopcrative concomitant ehe-ntoradiation plus surgery in patients with resectable oesophageal cancer: Updated analysis, Proc Ant Soc Clin Oncol 1997:16:abstr 983.
48. Hyants DM, Mamounas EP, Pelrelli N, Rock-ette H, Jones J, Wieand HS, Deutsch M, Wick-erham DL, Fisherr B, Wolntark N: A clinical trial to evaluate the worth of prcopcrative mul-t¡modality therapy in patients with operable carcinoma of the rectum: A progress report of the National Surgical Adjuvant Breast and Bowel Project Protocol R-03, Dis Colon Rectum 1997:40:131-139.
49. Baltershill P, Clissort S: Octreotide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in conditions associated with excessive peptide secretion, Drugs 1989:38:658-702.
50. Long RG, Peters JR, Bloom SR, Brown MR, Vale W, Rivier JE, Grahamc-Smith DG: Somatostatin, gastrointestinal peptides, and the carcinoid syndrome, Gut 1981:22:549-553.
51. Kvols L: Medical oncology considerations in patients with metastatic neuroendocrine carcinomas, Semin Oncol 1994:21 (suppl 13):55-60.
52. Oberg K: Neuroendocrine gastrointestinal tumours, Ann Oncol 1996;7:453-463.
53. Jacobsen MB, Hanssen LE: Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours: Report on a double-blind, randomized trial, J Intern Med 1995;237:269-275.
54. Rubin J, Ajani J, Schirmer W, Venook A, Bukowski A, Pommier R, Saltz L, Dandona P, Anthony L: Results of a randomized study of the safety, tolerability and efficacy of multiple double blind dose levels of octreotide acetate LAR given al four-week intervals versus open-labcl subcutaneous Sandostalin in malignant carcinoid syndrome, Proc Am Soc Clin Oncol 1997; 16:abstr 993.
55. Davies N, Kyaston H, Yates J, Taylor BA, Jenkins SA: Octreotide inhibits the growth and development of three types of experimental liver mctastases, Br J Surg 1995:82:840-843.
56. Van Eijck CIIJ, Slooter GD, Hofland U, Kort W, Jeekel J, Lamberts SW, Marquet RL: Somatostatin receptor-dependent growth inhibition of liver métastases by octreotide, Br J Surg 1994:81:1333-1337.
57. Weckbecker G, Raulf F, Stolz B, Bruns C: Somatostatin analogues for diagnosis and treatment of cancer, Pharmacol Ther 1993:60:245-264.
58. Davies N, Kynaston H, Yates J, Nott DM, Nash J, Taylor BA, Jenkins SA: Octreotide, the hepatic reticuloendothelial system and liver mctastases, Gut 1995:36:610-614.
59. Fassler JE, Hughes JH, Cataland S, et al: Somatostatin analogue: An inhibitor of angiogenesis? Biomcd Res 1988:9(suppl 1): 181-185.
60. Romani R, Morris DL: SMS 210.995 (Sandos-tatin) enhances in vitro effects of 5-fluorouracil in colorectal cancer, EurJ Surg Oncol 1995:21: 27-32.
61. Cascinu S, Del-Ferro E, Catalano G: A randomised trial of octreotide vs, best supportive care only in advanced gastrointestinal patients refractory to chemotherapy, Br J Cancer 1995: 71:95-101.
62. Pandha HS, Waxman J: Octreotide in malignant intestinal obstruction, Anticancer Drugs 1996;7(suppl 1):5-7.
63. Gebbia V, Carreca I, Testa A, Valcnza R, Curto G, Cannata G, Borscllino N, Latteri MA, Ci-polla C, Florcna M, et al: Subcutaneous octreotide versus oral loperamide in the treatment of diarrhoea following chemotherapy, Anticancer Drugs 1993:4:443-445.
64. Cascinu S, Fedcli A, Fedeli SL, Catalano G: Control of chemotherapy induced diarrhoea with octreotide in patients receiving 5-fiuoro-uracil, Eur J Cancer 1992:28:482-483.
65. Kane KF, Langman MJS, Williams GR: Antiproliferative responses of two human colorectal cancer cell lines:o vitamin D r arc differentially modified by 9-cis-rclinoic acid, Cancer Res 1996:56:623-632.
66. Zugmaicr G, Jäger R, Grage B, Gottardis MM, Havcmann K, Knabbe C: Growth-inhibitory effects of vitamin Danaloguesand retinoids on human pancreatic cancer cells, Br J Cancer 1996:73:1341-1346.
67. Thomas MG, Tebull S, Williamson RC: Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancercell line, Gut 1992;33:1660-1663.
68. Zhao X, Feldman D: Regulation of vitamin D receptor abundance and responsiveness during differentiation of ht-29 human colon cancer cells, Endocrinology 1993; 132:1808-1814.
69. Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer vitamin D compounds, J Natl Cancer Inst 1997:89:182-185.
70. Rietmüller G, Schncidcr-Gadickc E, Schlimok G, Schmiegel W, Raab R, HolTken K, Gruber R, Piehlmaier H, Hirche H, Pichlmayr R, Bug-gisch P, Witte J: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' Ccolorectal carcinoma, German Cancer Aid 17-! A Study Group, Lancet 1994; 343:1177-1183.
71. Giantonio BJ, Alpaugh RK, Schultz J, McAtcer C, Newton DW, Shannon B, Gucdcz Y, Kotb M, Vitek L, Pcrsson R, Gunnarson P-O, Kal-land T, Dohlsten M, Persson B, Weiner LM: Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monoclonal antibody-staphvlocoecal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer, J Clin Oncol 1997:15:1994-2007.
72. Blakev DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eekcrsley KP, Fitton JE, McDaid J, Melton RG, Niculcscu-Duvaz 1A, Pindcr PE, Sharma SK, Wright AF, Springer CJ: ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts, Cancer Res 1996:56:3287-3292.
73. Rasmussen H, Rugg T, Brown P, Baillet M, Millar A: A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer, Proc Am Soc Clin Oncol 1997;16:abstr 1538.
74. Roth JA, Nguvcn D, Lawrence DD, Kemp BL, Carrasco CH, Fcrson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pistcrs KMW, Putnam JB, Shea R, Shin DM, Walsh GL, Dolormcntc MM, Han C-L, Martin ED, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhvay T, Cal D: Retrovirus-mediated wild-tvpe pSi gene transfer to tumours of patients with lung cancer, Nat Med 1996:9:985-991.
75. Swisher SG, Roth JA, Lawrence DD, Kemp BL, Carrasco CH, Fossela FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pistcrs KM, Putnam JB, Schrump DS, Shin DM, Walsh GL: Adenoviral-mediatcd p53 gene transfer in patients with advanced non-sniall-cell lung cancer (NSCLC), Proc Am Soc Clin 1997;l6:abstr 1565.
76. Bischoff JR, Kint DH, Williams A, Hcisc C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johanncs A, Fattacy A, McCormick F: An adenovirus mutant that replicates selectively in p53-deFicien! human tumour cells, Science 1996:274:373-376.
77. Kirn DH, Hcise C, Mangold G, Von Hoff D: ONYX-015, a selectively replicating adenovirus, has antitumoral activity following iv administration alone and in combination with chemotherapy, Proc Am Soc Clin Oncol 1997; 16:abstr 1564.
78. Sikie BL Yuen AR, Halsey J, Fisher GA, Pribble JP, Smith RM, Dorr A: A phase I trial of an antisense oligonucleotide targeted to protein kinase C-a (ISIS 3521) delivered by 21-day continuous intravenous infusion, Proc Am Soc Clin Oncol 1997:16:abstr 741.